Adjuvants for human vaccines.

Adjuvants for human vaccines.
复制标题

DOI:
10.1016/j.coi.2012.03.008
复制
发表时间:
2012-06
影响因子:
7
通讯作者:
Reed SG
Reed SG
中科院分区:
医学2区
文献类型:
--
作者:
Alving CR;Peachman KK;Rao M;Reed SG

文献摘要

参考文献

被引文献

相似文献

通常,基于外国分子与模式识别受体(例如Toll-like受体)的先天分子相互作用,通常可以对单个佐剂进行合理选择。例如,最近已经用脂质体,油乳液或铝盐制剂配制了一种来自细菌的内毒素TLR4激动剂分子的单磷酸脂质A。抗原和佐剂与颗粒脂质或油成分的组合可能会揭示免疫力或功效的独特特性,但是与非人类灵长类动物或人类相比,在啮齿动物中有时会以不同的方式表现出不同的表现。新的佐剂,配方,显微注射装置和皮肤免疫的皮肤输送技术表明,辅助系统可以包括策略和递送机制的组合,用于独特配方的抗原和佐剂。
Rational selection of individual adjuvants can often be made based on innate molecular interactions of the foreign molecules with pattern recognition receptors such as Toll-like receptors. For example, monophosphoryl lipid A, a family of endotoxic TLR4 agonist molecules from bacteria, has recently been formulated with liposomes, oil emulsions, or aluminum salts for several vaccines. Combinations of antigens and adjuvants with particulate lipid or oil components may reveal unique properties of immune potency or efficacy, but these can sometimes be exhibited differently in rodents when compared to nonhuman primates or humans. New adjuvants, formulations, microinjection devices, and skin delivery techniques for transcutaneous immunization demonstrate that adjuvant systems can include combinations of strategies and delivery mechanisms for uniquely formulated antigens and adjuvants.
DOI: 10.1586/erv.10.174
发表时间: 2011-04
影响因子: 6.2
作者:
Bode C;Zhao G;Steinhagen F;Kinjo T;Klinman DM
通讯作者: Klinman DM
RIG-I 样受体的免疫信号传导。
DOI: 10.1016/j.immuni.2011.05.003
发表时间: 2011-05-27
期刊: Immunity
影响因子: 32.4
作者:
Loo YM;Gale M Jr
通讯作者: Gale M Jr
DOI: 10.1016/j.vaccine.2009.12.084
发表时间: 2010-03-11
期刊: VACCINE
影响因子: 5.5
作者:
Harandi, Ali M.;Medaglini, Donata;Shattock, Robin J.
通讯作者: Shattock, Robin J.
DOI: 10.1073/pnas.89.1.358
发表时间: 1992-01-01
影响因子: 11.1
作者:
FRIES, LF;GORDON, DM;ALVING, CR
通讯作者: ALVING, CR
DOI: 10.1371/journal.pone.0013460
发表时间: 2010-10-18
期刊: PloS one
影响因子: 3.7
作者:
Corbett HJ;Fernando GJ;Chen X;Frazer IH;Kendall MA
通讯作者: Kendall MA